A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Talquetamab is a medicine being studied for people with relapsed or refractory multiple myeloma. Multiple myeloma is a type of cancer affecting the bone marrow, the soft part inside bones where blood cells are made. The goal of this study is to see if talquetamab works well and is safe for patients at a certain dose.

Participants need to have been diagnosed with this type of cancer and have a certain health status. Women who might be pregnant must test negative for pregnancy before joining. Some people cannot join if they've used certain cancer therapies recently or have other medical conditions such as a recent stroke.

• The study involves taking doses of talquetamab.
• There may be risks, like possible side effects from the medication.
• Participants need to follow specific study rules and guidelines.

Joining a study can help doctors learn more about treating multiple myeloma, but it's important to consider the possible risks and time commitment. Always talk to your doctor to see if joining a study is right for you. 🩺